Henrik Barth1, Sven Crafoord2, Sten Andréasson3, Fredrik Ghosh3. 1. Department of Ophthalmology, Lund University Hospital, BMC B11, S-22184, Lund, Sweden. henrik.barth@med.lu.se. 2. Department of Ophthalmology, Faculty of Medicine and Health, Örebro University, Örebro University Hospital, Örebro, Sweden. 3. Department of Ophthalmology, Lund University Hospital, BMC B11, S-22184, Lund, Sweden.
Abstract
PURPOSE: Vitrectomy requires the substitution of the natural vitreous, as well as tamponading of retinal breaks. Clinically available alternatives such as gas and silicone oil have side effects such as inflammation, secondary glaucoma, cataract, and a need for head posturing. In this study, a hydrogel of cross-linked sodium hyaluronic acid (Healaflow(®)) is evaluated for use as a novel vitreous substitute. METHODS: A combined 25-20-gauge pars plana vitrectomy with posterior vitreous detachment was performed in the right eye of twelve pigmented rabbits, with subsequent injection of approximately 1 ml Healaflow(®). Clinical evaluation, measurement of intraocular pressure (IOP), and full-field ERG were performed postoperatively. The rabbits were sacrificed at different time-points between 42 and 105 days. After enucleation, the eyes were examined macroscopically, photographed, and prepared for histological examination with routine microscopy and immunohistochemistry. RESULTS: Healaflow(®) was successfully used with standard surgical procedures and remained translucent but did lose most of its viscosity during the postoperative period. One rabbit was lost due to unrelated causes. In two eyes iatrogenic partial retinal detachments were seen, and in two eyes significant cataract developed due to intra-operative complications. ERG-recordings revealed no toxic effect on rod or cone function. Routine microscopy and immunohistochemistry demonstrated normal morphology with some Müller cell activation (up-regulation of glial acidic fibrillary protein, GFAP) compared to unoperated eyes and no significant DNA-fragmentation (TUNEL-assay). CONCLUSIONS: Healaflow® did not affect retinal morphology or function negatively during long-term use as a vitreous substitute, making it highly interesting in this setting. An estimated retention time of a few weeks suggests potential for use as a short-term tamponade. Future work will include an increased ratio of cross-linking to prolong the structural integrity of the gel.
PURPOSE: Vitrectomy requires the substitution of the natural vitreous, as well as tamponading of retinal breaks. Clinically available alternatives such as gas and silicone oil have side effects such as inflammation, secondary glaucoma, cataract, and a need for head posturing. In this study, a hydrogel of cross-linked sodium hyaluronic acid (Healaflow(®)) is evaluated for use as a novel vitreous substitute. METHODS: A combined 25-20-gauge pars plana vitrectomy with posterior vitreous detachment was performed in the right eye of twelve pigmented rabbits, with subsequent injection of approximately 1 ml Healaflow(®). Clinical evaluation, measurement of intraocular pressure (IOP), and full-field ERG were performed postoperatively. The rabbits were sacrificed at different time-points between 42 and 105 days. After enucleation, the eyes were examined macroscopically, photographed, and prepared for histological examination with routine microscopy and immunohistochemistry. RESULTS: Healaflow(®) was successfully used with standard surgical procedures and remained translucent but did lose most of its viscosity during the postoperative period. One rabbit was lost due to unrelated causes. In two eyes iatrogenic partial retinal detachments were seen, and in two eyes significant cataract developed due to intra-operative complications. ERG-recordings revealed no toxic effect on rod or cone function. Routine microscopy and immunohistochemistry demonstrated normal morphology with some Müller cell activation (up-regulation of glial acidic fibrillary protein, GFAP) compared to unoperated eyes and no significant DNA-fragmentation (TUNEL-assay). CONCLUSIONS: Healaflow® did not affect retinal morphology or function negatively during long-term use as a vitreous substitute, making it highly interesting in this setting. An estimated retention time of a few weeks suggests potential for use as a short-term tamponade. Future work will include an increased ratio of cross-linking to prolong the structural integrity of the gel.
Authors: Charlotte Schramm; Martin S Spitzer; Sigrid Henke-Fahle; Gabriele Steinmetz; Kai Januschowski; Peter Heiduschka; Jürgen Geis-Gerstorfer; Tilo Biedermann; Karl U Bartz-Schmidt; Peter Szurman Journal: Invest Ophthalmol Vis Sci Date: 2012-02-02 Impact factor: 4.799
Authors: Blessing C Ilochonwu; Marko Mihajlovic; Roel F Maas-Bakker; Charis Rousou; Miao Tang; Mei Chen; Wim E Hennink; Tina Vermonden Journal: Biomacromolecules Date: 2022-06-23 Impact factor: 6.978
Authors: Nicholas L Cuccia; Suraj Pothineni; Brady Wu; Joshua Méndez Harper; Justin C Burton Journal: Proc Natl Acad Sci U S A Date: 2020-05-12 Impact factor: 11.205
Authors: Sven Schnichels; Nele Schneider; Christine Hohenadl; José Hurst; Andreas Schatz; Kai Januschowski; Martin S Spitzer Journal: PLoS One Date: 2017-03-01 Impact factor: 3.240
Authors: André Schulz; Silke Wahl; Annekatrin Rickmann; Jannine Ludwig; Boris V Stanzel; Hagen von Briesen; Peter Szurman Journal: Transl Vis Sci Technol Date: 2019-06-28 Impact factor: 3.283
Authors: André Schulz; Annekatrin Rickmann; Silke Wahl; Anja Germann; Boris Viktor Stanzel; Kai Januschowski; Peter Szurman Journal: Transl Vis Sci Technol Date: 2020-12-18 Impact factor: 3.283
Authors: Jose Hurst; Annekatrin Rickmann; Nele Heider; Christine Hohenadl; Charlotte Reither; Andreas Schatz; Sven Schnichels; Kai Januschowski; Martin S Spitzer Journal: Front Pharmacol Date: 2022-03-02 Impact factor: 5.810